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Abstract
The neuropeptide oxytocin (OXT) has generated considerable interest as potential treatment for psychiatric disorders,
including anxiety and autism spectrum disorders. However, the behavioral and molecular consequences associated with
chronic OXT treatment and chronic receptor (OXTR) activation have scarcely been studied, despite the potential therapeutic
long-term use of intranasal OXT. Here, we reveal that chronic OXT treatment over two weeks increased anxiety-like
behavior in rats, with higher sensitivity in females, contrasting the well-known anxiolytic effect of acute OXT. The increase
in anxiety was transient and waned 5 days after the infusion has ended. The behavioral effects of chronic OXT
were paralleled by activation of an intracellular signaling pathway, which ultimately led to alternative splicing of
hypothalamic corticotropin-releasing factor receptor 2α (Crfr2α), an important modulator of anxiety. In detail, chronic OXT
shifted the splicing ratio from the anxiolytic membrane-bound (mCRFR2α) form of CRFR2α towards the soluble CRFR2α
(sCRFR2α) form. Experimental induction of alternative splicing mimicked the anxiogenic effects of chronic OXT, while
sCRFR2α-knock down reduced anxiety-related behavior of male rats. Furthermore, chronic OXT treatment triggered the
release of sCRFR2α into the cerebrospinal fluid with sCRFR2α levels positively correlating with anxiety-like behavior. In
summary, we revealed that the shifted splicing ratio towards expression of the anxiogenic sCRFR2α underlies the adverse
effects of chronic OXT treatment on anxiety.
Introduction
Neuropeptides and their receptors are established modulators
of neuronal activity, shaping multiple behavioral and phy-
siological responses to environmental stimuli. Neuropeptide
signaling is, therefore, an important target for the develop-
ment of pharmacological treatments of psychopathologies,
such as autism-spectrum, anxiety and substance-use disorders,
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or schizophrenia, among others [1, 2] associated with social
and emotional dysfunctions. In this context, the neuropeptide
oxytocin (OXT) has received considerable attention over the
last decades due to its profound prosocial, fear-reducing and
anxiolytic effects demonstrated both in human and animal
studies [3]. Studies in rodents have shown that the multiple
behavioral effects of acute OXT can be induced within the
paraventricular nucleus of the hypothalamus (PVN) [4, 5],
central amygdala [6–8], lateral septum [9, 10], and cortical
[11] and brainstem [12] regions.
OXT is synthesized in the PVN and supraoptic nuclei of
the hypothalamus, where it is released somato-dendritically
in response to stressful and fear-enhancing stimuli
[3, 13, 14]. Such locally-released OXT, e.g., within the
PVN, as well as acute local OXT infusions, exert robust
anxiolytic effects in rats, shown in several relevant beha-
vioral tests [4, 5]. Within the PVN, OXT also acts as neu-
romodulator of social behaviors [15, 16] and physiological
functions including the regulation of the hypothalamic-
pituitary-adrenal axis and stress-induced secretion of adre-
nocorticotropin (ACTH) and corticosterone [17, 18].
On a molecular level, the G protein-coupled OXT
receptor (OXTR) is linked to multiple intraneuronal sig-
naling cascades [3, 19]. In brief, the G protein αq subunit is
at the basis of activation of protein kinase C (PKC) [20],
whereas the β/γ subunit activates Ca2+-influx through
transient receptor potential vanilloid type 2 (TRPV2) and
other Ca2+ channels [3, 21]. This is followed by the
recruitment of mitogen-activated protein kinase (MAPK)
kinase (MEK1/2) signaling [21] and protein synthesis [20].
Both MEK1/2 signaling and protein synthesis are necessary
for the acute anxiolytic effect of OXT in the PVN of male
[4, 20] and virgin female [5] rats. In addition, the acute
anxiolytic activity of OXT in the PVN is enhanced under
mild stress conditions [4] indicating an interaction of OXT
and central stress regulation. Indeed, OXT has been found
to reduce and delay the hypothalamic expression of
corticotropin-releasing factor (Crf) [22, 23], and reciprocal
interactions with the anxiolytic [24, 25] transmembrane
CRF receptor 2α (mCRFR2α) signaling in the PVN and bed
nucleus of the stria terminalis have been described [26, 27].
OXT was found to be behaviorally effective not only in
laboratory animals [3, 28], but also in humans, where syn-
thetic OXT can be applied intranasally [29, 30]. In most
human studies, OXT has been applied acutely so far, and,
even at relatively high doses, persistent side effects have not
been reported [31, 32]. However, we and others have found
adverse effects on anxiety [33], fear [34], and social beha-
viors [35–37] after chronic OXT application, or otherwise
artificially enhanced OXT signaling, in rodents. For exam-
ple, we have recently observed a dose-dependent anxiogenic
effect in mice following continuous intracerebroventricular
(icv) infusion of OXT using osmotic minipumps, with a
dose of 10 ng/h OXT increasing anxiety-like behavior after
14 days [33]. These adverse behavioral consequences were
accompanied by a reduction in intracerebral OXTR expres-
sion [33, 35]. In line with the described consequences of
chronic OXT treatment and increased OXTR-mediated sig-
naling, viral vector-induced overexpression of the OXTR in
the lateral septum enhanced contextual fear in socially
defeated mice [34]. Only in female rats with genetically
determined high anxiety [38] and in lactating females [39], a
beneficial anxiolytic effect of icv OXT infusion over 5 days
was found. However, the molecular mechanisms underlying
the adverse effects of chronic or prolonged OXT actions on
anxiety, fear, or social behavior, in contrast to its beneficial
acute effects, have mostly been disregarded, but ought to be
carefully considered before OXT can be used as a treatment
option for psychiatric disorders [28, 29, 40–42]. So far, the
few human studies employing repeated intranasal adminis-
tration of OXT over several days or weeks focused on social
parameters and almost consistently reported a lack of major
adverse side effects, such as self-reported anxiety or changes
in blood pressure, osmotic homeostasis or bone metabolism
[43, 44], but more detailed and targeted studies are missing.
Therefore, in the present study we addressed the mole-
cular mechanisms causing the anxiogenic effect of chronic
icv OXT treatment in rats. While we found that chronic
OXT enhanced anxiety-like behavior in both male and
female rats, the underlying mechanism appeared to be
sexually dimorphic. Uniquely in males, chronic OXT
recruited a so far unknown intracellular signaling pathway
in the PVN downstream of the OXTR, which includes the
MAPK-controlled phosphorylation of the transcription
factor myocyte enhancer factor 2 isoform A (MEF2A) [45].
In more detail, all MEF2 isoforms are crucial transcription
factors controlling basic cellular functions associated with
learning and memory consolidation, dendrite morphogen-
esis, excitatory synapse formation in hippocampal neurons
during development [46], and some variants are associated
with autism spectrum disorder [47, 48]. The MEF2A-
specific phospho sites Ser408, Thr312, Thr319 assessed in
this study have different transcriptional effects, with Ser408
being repressive, and Thr312 and Thr319 being transcrip-
tion activators. Further downstream of MEF2A, we could
reveal that chronic icv OXT induced alternative splicing of
Crfr2α to its soluble form (sCRFR2α). Interestingly,
chronic OXT also triggered the release of the splice variant
sCRFR2α into the cerebrospinal fluid (CSF), and we further
found that sCRFR2α levels in CSF positively correlated
with anxiety-like behavior. As a final proof of the invol-
vement of sCRFR2α in the adverse behavioral con-
sequences of chronic OXT treatment, we manipulated
Crfr2α splicing in favor of its soluble form and could
confirm its anxiogenic regulatory capacity. Taken together,
our data provide a mechanistic explanation of the
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anxiogenic effect of chronic OXT in male rats, and illustrate
the intimate relationship between the OXT and CRF sys-
tems. Consequently, they challenge the concept of treating
emotional or social dysfunctions with repetitive or chronic
OXT application [40, 49–51], and forward sCRFR2α as a
novel target for the development of anxiolytics.
Material and methods
A detailed list of chemicals and material used in this study
can be found in Supplementary Table S1. Primers and
antibodies are listed in Supplementary Tables S2 and S3.
Animals and husbandry
Adult male and female Wistar rats (Charles River,
Germany, 250–300 g) were housed under standard tempera-
ture- and humidity-controlled conditions with food and water
ad libitum. All animal experiments were performed between
08:00–11:00 according to the ARRIVE guidelines [52] and
recommendations from the National Institutes of Health, and
approved by the government of Unterfranken, Germany. In all
in vivo experiments, the experimenter was blind to the
treatment. Group sizes were estimated upon power analysis,
based on results from previous publications [5, 22, 33, 38].
Animals were randomly assigned to experimental groups,
complying with equal mean body weight between groups.
Pre-established exclusion criteria for animals included com-
plications during surgery, poor histological quality, and gen-
eral poor health condition.
Chronic icv OXT infusion
Osmotic minipumps (Alzet, model 1002, flow rate 0.25 μl/
h, 14 days) were filled with either vehicle (VEH; Ringer’s
solution, B. Braun Melsungen AG, Germany), 4 μM or 40
μM OXT (Bachem, Bubendorf, Switzerland) to allow the
infusion of 1 ng/h or 10 ng/h of OXT, and were implanted
subcutaneously [38]. On day 13, rats were mildly stressed
by 5-min exposure on the elevated platform [4, 53], and
tested in the light-dark box (LDB) [15, 38] on day 14.
Another rat cohort was tested in the LDB on day 14 without
prior platform exposure.
Acute icv and local intra-PVN infusions
Acute icv or intra-PVN infusions of VEH, OXT (icv:
100 ng/5 μl; local: 10 ng/0.5 μl per side, corresponding to
20 μM), antisauvagine-30 (ASV, 500 ng/0.5 μl per side;
Tocris Bioscience, Bristol, UK) or stresscopin (SCP, 3 μg/
0.5 μl per side, 25 min prior testing; Phoenix
Pharmaceuticals, Inc., Burlingame, USA) were performed
7 days after stereotaxic implantation of guide cannulas
targeting the region of interest and recovery as described
before [4, 15, 53].
Infusion of GapmeRs or target site blockers (TSBs)
In order to assess the behavioral consequences of selective
manipulation of mCRFR2α/sCRFR2α ratio, bilateral intra-
PVN (−1.7 mm bregma, ±0.3 mm lateral, 8.2 mm deep)
infusions of locked nucleic acid antisense oligonucleotides
(so-called GapmeRs), TSBs or scrambled control oligonu-
cleotides (0.5nmol/0.5 μl, Qiagen, Hilden, Germany, Sup-
plementary Material) were performed 7 days prior to LDB
testing, and 8 days prior to testing in the open field (OF) and
for social preference [54].
Behavioral tests
Anxiety-related behavior was assessed in the LDB, elevated
plus-maze (EPM), or OF during 5-min sessions [4]. For
behavioral specificity of OXT effects in the PVN, social
motivation was tested in the social preference test [54].
Locomotion (distance traveled) was determined by Noldus
EthoVision XT 14 software.
Tissue, plasma, and organ processing
After behavioral testing, brains were removed for regional
protein and RNA isolation, histological verification of
cannula placement or in situ hybridization (ISH). For CSF
sampling from the cisterna magna, rats were terminally
anaesthetized with urethane, before trunk blood was col-
lected for analysis of ACTH and corticosterone levels. The
weights of adrenal glands, heart, and thymus were taken,
and oil-red staining of lipid vesicles in the adrenal cortex
was conducted [55].
Cell lines and primary cultures
Authentication of rat hypothalamic H32 cells [56] was exe-
cuted on the basis of OXTR sequencing, morphology, and
marker gene expression. Potential mycoplasma contamination
was assessed on a regular basis. Cells were cultured in
DMEM/F12 (Sigma-Aldrich, Darmstadt, Germany) with 10%
heat inactivated FBS advanced (Capricorn, Ebsdorfergrund,
Germany), and penicillin/streptomycin (Sigma-Aldrich,
Darmstadt, Germany). Cells were sub-cultured by gentle
trypsinization (Gibco™, Thermo Fisher Scientific, Waltham,
USA) at 80% confluence. For transcriptional analyses, cells
were seeded at a density of 3 × 106 cells in a 25 cm² cell
culture dish the day before experiment, pre-incubated in
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serum-free stimulation medium for 1 h and stimulated with
the respective treatment.
Primary neuronal and glial cultures were obtained from
embryonic day 18 rat hypothalami [22].
In silico analysis of MEF2 targets
Analysis of potential MEF2 targets by assessment of DNA
binding regions was performed using the Geneious prime
software (Geneious prime 2019.0.3; https://www.geneious.
com).
MEF2A knockdown studies
H32 cells were seeded 24 h prior to transfections. For
MEF2A knockdown, siRNA or scrambled RNA (scrRNA)
as control (1 nM; #SR504191, OriGene, Rockville, USA,
Supplementary Material) were transfected with Lipofecta-
mine RNAiMAX (Invitrogen by Thermo Fisher Scientific,
Waltham, USA) and incubated for 72 h at 37 °C and 5%
CO2. After 48 h, cells were stimulated with either 100 nM
OXT or VEH for another 24 h.
Chromatin-IP
H32 cells were stimulated as described above, MEF2A-
DNA complexes were fixed for 10 min, lysed (Supple-
mentary Material), sheared by sonication, precleared with
Sepharose beads, and MEF2A complexes isolated with a
specific MEF2A antibody (Supplementary Material). DNA
fragments were identified by qPCR with primers directed
against Crfr2-specific MEF2A binding sequences (Supple-
mentary Material).
Nano-Glo® HiBiT extracellular detection system
The integration site of the HiBiT-containing Ultramer®
ssDNA donor sequence was directly upstream of Exon 6 of
the Crfr2α gene (Supplementary Material). The donor
sequence was delivered together with the RNP complex
(Alt-R® CRISPR-Cas9 system, IDT, Coralville, USA) by
using Lipofectamine™ RNAiMAX. Membrane-bound
CRFR2α (mCRFR2α) was visualized using the Nano-
Glo® HiBiT Extracellular Detection System according to
the manufacturer’s instructions (Promega, Mannheim,
Germany). Luminescence was measured at the GloMax
Explorer (Promega, Mannheim, Germany).
Immunofluorescent labeling for co-localization of
sCRFR2α, OXTR, and OXT in OXTR-reporter mice
OXTR-reporter mouse brains (OXTR-Venus [12]) were
immunostained (Supplementary Material). Colocalization
of sCRFR2α, OXTR and OXT was analyzed using the
BioVoxxel Version of Fiji and plugin JACoP. Antibody
specificity was assessed by pre-incubation with immunizing
peptide, and in knockdown and overexpression systems
(Supplementary Fig. S1A–D).
Immunocytochemistry
To visualize sCRFR2α expression, immunocytochemistry
in primary hypothalamic cells was performed (Supple-
mentary Material).
Western Blot and Dot Blot analysis
For Dot Blot analysis, 10 μg of total protein was pipetted
onto a Nitrocellulose membrane, allowed to dry and pro-
cessed identical to the Western Blot protocol previously
described [20, 22, 45]. Detection was performed using a
specific sCRFR2α antibody [57]. Loading was controlled
by Ponceau red staining.
ISH for OXT mRNA
To assess hypothalamic OXT mRNA, ISH was conducted
[33] using a 35S-labeled probe specific for rats and mice
(Supplementary Material).
Receptor autoradiography for OXTR and V1aR
binding
To quantify hypothalamic OXTR and V1aR binding,
receptor autoradiography was performed on 16-μm coronal
cryostat sections [39] (Supplementary Material).
ACTH and corticosterone analyses
Plasma samples were assayed using ELISA (IBL, Hamburg,
Germany) for ACTH (sensitivity 0.22 pg/ml, intra-assay
and inter-assay coefficients of variation ≤ 7.1%) and corti-
costerone (sensitivity < 1.63nmol/l, intra-assay and inter-
assay coefficients of variation ≤ 6.35%).
RNA isolation for qPCR and PCR array
To analyze mRNA expression of target genes in punches
from PVN, hippocampus, and prefrontal cortex, RNA was
isolated as described before [22].
To isolate RNA from stimulated H32 cells, the medium
was aspirated, cells were washed with PBS, and RNA was
isolated according to manufacturer’s instruction (Macherey
Nagel, Düren, Germany).
300 ng of total RNA per sample were used for reverse
transcription into cDNA using Super Script IV First strand
J. Winter et al.
Synthesis System for RT-PCR (Invitrogen; Supplementary
Material). The custom RT2 PCR array (330171
CLAR25389) was purchased from Qiagen (Hilden, Ger-
many) and pipetted according to the manufacturer’s
protocol.
TransAM MEF2 binding kit
Protein samples were collected according to the manu-
facturer’s protocol (Active Motif, Rixensart, Belgium), and
20 μg protein was loaded onto the pre-coated 96 well plate.
MEF2A and MEF2C subform-specific antibodies from Ori-
Gene/Acris (Rockville, USA; Supplementary Material) were
used. Fluorescence was determined at 450 nm in a plate
reader (FluoStar Optima, BMG LABTECH, Ortenberg,
Germany).
Statistical analysis
Parametric one-way (factor treatment) or two-way (factors
treatment x time) analysis of variance (ANOVA), followed
by Holm Sidak post hoc correction, were performed for
statistical analyses of behavioral and molecular experiments
(Sigma Plot, version 11.0.0.75, Systat Software). Data sets
were analyzed for normal distribution using the
Shapiro–Wilk test. Non-parametric data was analyzed by
Kruskal–Wallis ANOVA on ranks and Tukey post hoc test.
Separate parametric t-test between two groups or non-
parametric Mann–Whitney U tests were performed. Data
outliers were defined as above or below mean ± 2x standard
deviation. Statistical significance was accepted at p < 0.05.
Data are presented as mean ± standard error of the
mean (SEM).
Results
Chronic OXT dose-dependently induces an
anxiogenic phenotype
After 14 days of chronic icv OXT infusion, and one day
after 5-min exposure to the elevated platform, rats were
tested in the LDB (Fig. 1A). Compared to VEH controls,
males treated with the high (10 ng/h), but not low (1 ng/h),
dose of OXT spent less time in the light box, demonstrating
an anxiogenic effect of chronic OXT (Fig. 1B, C). The
increase in anxiety contrasted with the anxiolytic effect seen
after acute OXT infusion into the PVN under otherwise
identical experimental conditions (Fig. 1D, E), and with the
absence of any effect on anxiety-like behavior after acute
icv infusion (Supplementary Fig. S2A [38]). The anxio-
genic phenotype was transient and waned within five days
after termination of chronic OXT infusion (Supplementary
Fig. S2B). In females, the lower dose increased anxiety-like
behavior, indicating seemingly higher sensitivity, while the
higher dose was without effect in the LDB (Supplementary
Fig. S2C). Chronic OXT-induced anxiogenesis was not
accompanied by changes in locomotor activity, neither in
males nor in females (Supplementary Table S4). Impor-
tantly, chronic OXT had no effect on the expression of
hypothalamic OXT and AVP, their receptors, or on OXTR
and V1aR binding in various brain regions (Supplementary
Table S5). Also, plasma ACTH and corticosterone levels, as
well as other peripheral parameters remained unchanged
after chronic OXT (Supplementary Tables S5 and S6 and
Supplementary Fig. S2D).
Chronic OXT treatment recruits the transcription
factor MEF2A
In PVN protein extracts, we observed increased phosphor-
ylation, reflecting activation, of the MAP kinases MEK1/2
(at 1 and 10 ng/h) and ERK1/2 (at 10 ng/h) after chronic
OXT infusion in males, whereas no such activation was
found in females (Fig. 2A, B, Supplementary Fig. S3A, B).
Moreover, chronic OXT (10 ng/h) resulted in elevated total
protein levels of MEF2A (Fig. 2C), and this was accom-
panied by increased MEF2A activity, as indicated by
increased MEF2A DNA binding in PVN tissue lysates of
male rats (Fig. 2D, Supplementary Fig. S3C). The observed
phosphorylation of the transcription activation sites Thr312
and Thr319 reflects elevated MEF2A activity, whereas the
MEF2A inhibitory site Ser408 was dephosphorylated
(Fig. 2E). Thus, chronic OXT activates MEF2A in the PVN
of male rats (Supplementary Table S5 and Supplementary
Fig. S3D). In contrast, acute icv OXT failed to enhance
MEF2A activity (Supplementary Fig. S3E). Thus, OXTR-
coupled signaling underlying the acute anxiolytic effect in
the PVN does not involve the activation of MEF2A
(Fig. 2D).
Five days after chronic OXT infusion had ended,
MEF2A-DNA binding capacity was similar to that seen in
VEH-treated rats (Fig. 2D), indicating that MEF2A activa-
tion is reversible. The activation of MEF2A in the PVN of
chronically OXT-infused male rats appeared to be highly
specific, as none of the other related kinases tested,
including p38, p90rsk, and MSK, showed any significant
changes in phosphorylation (Fig. 2F). In addition, the
phosphorylation pattern of the closely related MEF2C,
strongly expressed in the PVN and linked to OXTR sig-
naling [58], remained unchanged at Ser59, the regulatory
site inducing DNA binding (Fig. 2F). Consequently, DNA
binding of MEF2C remained unaffected in the group treated
with 10 ng/h OXT (Supplementary Fig. S3F).
In conclusion, chronic central infusion of high OXT
results in MEF2A activation in the PVN of male rats, and
Chronic oxytocin-driven alternative splicing of Crfr2α induces anxiety
increased anxiety-related behavior. However, recruitment of
MEF2A does not underlie the anxiogenic effect induced by
infusion of the low dose of OXT in virgin female rats. Thus,
the intracellular mechanisms causing anxiogenesis in
females are distinct from those in males, and need further
investigation.
MEF2A shifts the expression of membrane-bound to
soluble CRFR2α in the PVN
To identify potential MEF2A target genes, we used a
custom-designed PCR array that targets genes in the PVN
that 1) are related to MEF2A functions, such as synaptic
Fig. 1 Chronic icv OXT infusion increases anxiety in male rats. A
Schematic of the chronic OXT (cOXT) infusion paradigm (created
with BioRender.com). Osmotic minipumps (flow rate 0.25 μl/h, infu-
sion duration 14 days) were filled with vehicle (VEH), 4 or 40 μM
OXT, corresponding to 1 and 10 ng/h of OXT release rates, respec-
tively, subcutaneously implanted and connected to the lateral ventricle
of rats via polyethylene tubing. Day 1 marks the start of infusions.
After 13 days, rats were mildly stressed by exposure to the elevated
platform (EPF) for 5 min, and tested in the light-dark box (LDB) on
day 14. Brain samples were collected immediately after LDB expo-
sure. B cOXT decreased the time spent in the light box in a dose-
dependent manner. Shown is the percentage of time spent in the lit box
(LB). Data are represented as mean ± SEM. F(2;50)= 10.131; p <
0.001; Holm-Sidak *p < 0.001 vs VEH; n(VEH)= 15, n(1 ng/h, 10 ng/
h)= 18. C Representative heat maps of rat location in the LDB;
treatments as described in B. D Acute bilateral infusion of OXT
(acOXT; 20 μM, 0.01nmol/0.5 μl per side) into the paraventricular
nucleus (PVN) reduced anxiety-related behavior. Male rats were tested
in the LDB or elevated plus-maze (EPM) 10 min after infusion, and 24
h after EPF exposure. Shown is the percentage of time spent in the LB
or open arm (OA). Data are represented as mean ± SEM. One-tailed
Student’s t test, p < 0.01, df= 6; n(VEH)= 4, n(acOXT)= 4. E
Representative heat maps of rat location in the LDB and EPM after
intra-PVN VEH or acOXT treatment.
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connectivity or neuronal plasticity, 2) contain one or more
MEF2A binding sequences, and 3) have been associated
with stress- or anxiety-like behaviors. After high chronic
OXT treatment, we found distinct alterations in gene
expression of closely related genes, of which those of
membrane-bound and soluble CRFR2α were particularly
striking (Fig. 3A), because of the known OXT and CRF
interactions [22, 59], as well as the involvement of CRF in
stress and anxiety [25, 60–62]. The expression of membrane-
bound CRFR2α (mCRFR2α; Fig. 3A) was reduced, whereas
that of the alternative splice variant, soluble CRFR2α
(sCRFR2α), was increased in PVN tissue of chronic OXT-
treated male, but not female (Supplementary Fig. S4A), rats,
when compared with VEH-treated animals. Alternative
splicing was confirmed by endpoint PCR demonstrating that
sCrfr2α expression, which was below the detection limit in
VEH controls, is effectively induced after chronic OXT
(Fig. 3B upper panel). At the protein level, OXT-treated
males expressed more sCRFR2α (88.3%) in proportion to
mCRFR2α (11.7%; Fig. 3B lower panel and 3 C). No such
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effect was seen after an acute local administration of OXT
(Fig. 3D). In silico analysis revealed that the coding
sequence of the Crfr2α gene harbors seven potential MEF2A
binding sites, two of them present within Exon 6 (base pairs
791–800 and 908–917). We performed ChIP analysis
(Supplementary Fig. S4B) with H32 cells, which express
MEF2A, OXTR (Supplementary Fig. S1A, B) and CRFR2α
and found MEF2A binding to the Crfr2α gene especially
within Exons 2 and 6 (Supplementary Fig. S4B). Further-
more, selective MEF2A knockdown by means of siRNA
strongly reduced both mCRFR2α and sCRFR2α expression
in H32 cells, highlighting the necessity of MEF2A to induce
Crfr2α gene transcription (via binding to Exon 2) and to
promote alternative splicing (via binding to Exon 6; Fig. 3E).
In confirmation of the presence of the OXTR-MEF2A-
sCRFR2α cascade within OXTR-expressing PVN neurons,
we found that OXTR (as revealed by a Venus signal) and
sCRFR2α are partially co-expressed in the PVN of OXTR
reporter mice [12], whereas almost no co-expression of
sCRFR2α with V1aR or V1bR was detectable (Fig. 3F–I).
Chronic OXT promotes the release of sCRFR2α
in vitro
To identify and visualize mCRFR2α in H32 cells, we
integrated a spliceable tag (HiBiT) into Exon 6 of Crfr2α by
means of CRISPR-Cas9. This tag was visualized by adding
the LgBiT substrate to the cell culture medium (Fig. 4A).
The luminescent signal that forms following binding of
LgBiT and HiBiT detects mCRFR2α in live cells. We found
Fig. 2 Recruitment of MAPK and MEF2A by chronic OXT infu-
sion in the PVN of male rats. A cOXT at low and high doses
increased MEK1/2 phosphorylation in the PVN after 14 days. Data are
represented as mean ± SEM. Kruskal–Wallis H= 8.396; p= 0.015;
Dunn’s Method *p < 0.05 vs VEH; n(VEH; 1 ng/h)= 7, n(10 ng/h)=
6. B ERK1/2 phosphorylation was increased by 10 ng/h cOXT treat-
ment; n(VEH; 1 ng/h; 10 ng/h)= 7; pERK1: F(2;20)= 9.672; p=
0.001; Holm-Sidak *p= 0.001 VEH, 1 ng/h vs 10 ng/h; pERK2:
Kruskal–Wallis H= 10.293 p= 0.006; Tukey Test VEH vs 10 ng/h
*p < 0.05, 1 ng/h vs 10 ng/h *p < 0.05. C MEF2A total protein
expression increased in PVN lysates of 10 ng/h cOXT-treated male
rats. Kruskal–Wallis H= 7.156, p= 0.028; Dunn’s Method *p < 0.05
VEH versus 10 ng/h; n(VEH)= 6, n(1 ng/h)= 6, n(10 ng/h)= 7. D
MEF2A DNA binding activity increased in PVN lysates after 14 days
of chronic OXT at both doses and mild stress. Values are normalized
to VEH. F(2;29)= 8.262, p= 0.002, Holm-Sidak *p= 0.05 vs VEH;
n(VEH)= 7, n(1 ng/h)= 7, n(10 ng/h)= 16. In contrast to 14 days of
cOXT treatment, MEF2A binding activity returned to basal, 5 days
after the infusion had stopped (cOXT d14+ 5). Data are represented as
fold changes in DNA-binding activity ±SEM. F(2,14)= 2.316, p=
0.141; n(VEH)= 5, n(1 ng cOXT)= 5, n(10 ng cOXT)= 5. No effects
of acute intra-PVN OXT infusions have been observed on local
MEF2A binding activity. t= 0.0938; two-tailed p value= 0,927, n
(VEH)= 6, n(OXT)= 7; n for all groups n= 7. E Phosphorylation of
Thr312 and Thr319 within MEF2A increased in both the high and the
low treatment group, while Ser408 phosphorylation decreased after
cOXT at 10 ng/h. pMEF2A Thr312: Kruskal–Wallis H= 9,106, p=
0.011; Tukey Test VEH vs 1 ng/h *p < 0.05; n(VEH)= 7, n(1 ng/h)=
7, n(10 ng/h)= 7. pMEF2A Thr319: F(2;17)= 41.139; p < 0.001;
Holm-Sidak *p= 0.05 VEH versus 1 ng/h and 10 ng/h, and 1 ng/h
versus 10 ng/h; n(VEH)= 6, n(1 ng/h)= 6, n(10 ng/h)= 6. pMEF2A
Ser408: F(2;23)= 4.614; p= 0.022; Holm-Sidak *p= 0.033 VEH
versus 10 ng/h cOXT; n(VEH)= 7, n(1 ng/h)= 10, n(10 ng/h)= 7. F
Heat map of expression and phosphorylation levels of second mes-
senger kinases and transcription factors downstream of the OXTR as
analyzed by Western blot. Fold change below 1 (red) indicates
downregulation, fold change of 1 (yellow) indicates no change, fold
change bigger than 1 indicates upregulation (green). p values vs VEH
included; n.s. not significant; n for all groups n= 7.
J. Winter et al.
that luminescence intensity dropped in OXT-treated cells
(100 nM, 24 h), indicating reduced membrane incorporation
of mCRFR2α (Fig. 4B). In parallel, sCRFR2α content
increased tenfold in the cell culture medium (Fig. 4C)
demonstrating OXT-induced release of sCRFR2α from H32
cells. In addition, staining of primary hypothalamic cells
revealed punctate sCRFR2α immunoreactivity in neurons
and glial cells, reflecting vesicular localization (Fig. 4D).
Changes in mCRFR2α/sCRFR2α ratio result in
increased anxiety
To determine whether sCRFR2α is released in vivo, we
sampled CSF from the cisterna magna of male rats and
found detectable amounts of sCRFR2α (Fig. 5A). In con-
trast, sCRFR2α was not detectable in cerebellum tissue
[57], confirming the specificity of the dot blot analysis.
Next, we specifically knocked down the sCRFR2α splice
variant in the PVN by local infusion of GapmeRs [63] and
Fig. 3 MEF2A-dependent regulation of OXT receptor target genes
after cOXT treatment. A PCR array: Expression of
MEF2A-regulated candidate genes after 10 ng/h cOXT treatment. Data
calculated by ΔΔCT and presented as fold change vs. VEH. Fold
changes > 1, upregulated mRNA expression, fold changes < 1,
downregulated mRNA expression. n(VEH)= 5, n(10 ng/h cOXT)= 6.
Pax3 *p= 0.021, Crfr2α *p= 0.02, sCrfr2α #p= 0.07, Pax2 *p=
0.05. B Upper panel: Representative example of 3 male rat PVN
cDNA samples showing mCrfr2α (upper band, 400 bp) in VEH-treated
animals, and mCrfr2α / sCrfr2α (lower band, 300 bp) expression in the
cOXT treatment groups. Lower panel: Western Blot of mCRFR2α
(~50 kDa) and sCRFR2α (~30 kDa) levels after VEH, 1 or 10 ng/h
cOXT infusion and mild stress, using a polyclonal pan-CRFR2 anti-
body. C Ratio of mCRFR2α and sCRFR2α protein expression after
cOXT and mild stress in male rats, shifting in the favor of sCRFR2α
following treatment. Data are represented as mean ± SEM. F(2;15)=
5.311, p= 0.021; Holm-Sidak p= 0.019 10 ng/h vs VEH; n(VEH)=
6, n(1 ng/h)= 5, n(10 ng/h)= 6. D Treatment with acOXT had no
effects on the ratio of mCRFR2α/sCRFR2α protein expression in % in
the PVN of male rats. Data are represented as mean ± SEM. t= 0.784
with 11 degrees of freedom, two-tailed p value= 0.450; n(VEH)= 6,
n(OXT)= 7. E siRNA-mediated knockdown of MEF2A in H32 cells
incubated with 100 nM OXT decreased mCRFR2α and sCRFR2α
protein levels, indicating a central role for MEF2A in the transcription
of the CRFR2 gene. Data represented as mean ± SEM. mCRFR2α:
Mann–Whitney Rank Sum Test <0.001, *p= 0.002; sCRFR2α: t=
2.574 with 10 degrees of freedom; one-tailed *p value= 0.0138, both
vs. respective scr (scrambled) control; n(scr)= 6, n(MEF2A kd)= 6. F
Representative stainings showing co-localization of OXT-neurophysin
I (green), sCRFR2α (magenta), and OXTR-Venus (yellow) in the PVN
(indicated by white dotted line) of male OXTR-Venus reporter mice.
G Representative staining showing colocalization of OXT (green),
sCRFR2α (magenta), and V1bR (yellow) in the PVN of male Wistar
rats. H Pearson and Manders overlap coefficient of OXTR, OXT, and
sCRFR2α positive neurons reveal substantial (45–64%) overlap
between the OXTR, OXT, and sCRFR2α. I Pearson and Manders
coefficient reveal partial (24–37%) overlap of V1a/b and sCRFR2α in
the PVN. OXT-neurophysin and sCRFR2α show similar co-expression
(~60%) in rats and mice, indicating a comparable expression pattern of
the sCRFR2α in both species.
Fig. 4 Chronic OXT promotes the release of sCRFR2α in vitro.
A Schematic representation of HiBiT-mediated signaling in H32
cells stimulated with VEH or OXT for 24 h (created with BioR-
ender.com). B Assessment of mCRFR2α membrane expression by
tagging the transmembrane domain encoded in Exon 6 with a
HiBiT-tag. Membrane expression is indicated by luminescence
caused by extracellular HiBiT-LgBiT interaction. Stimulation for
24 h with 100 nM OXT decreased the luminescent signal, indicating
alternative splicing of Exon 6 and, therefore, reduced membrane
expression of CRFR2α. Data presented as absolute values of mean
luminescence ±SEM. Mann–Whitney Rank Sum Test, *p ≤ 0.001, n
(VEH)= 20, n(OXT)= 12. C Cell culture supernatants taken from
HiBiT-expressing cells (as shown in B) reveal sCRFR2α release
into the cell culture medium, which was 10-fold higher after sti-
mulation with 100 nM OXT over 24 h. Data shown as average gray
intensity relative to total protein Ponceau red staining.
Mann–Whitney Rank Sum Test, *p= 0.029; n(VEH/OXT)= 4.
Right panel: Representative Dot Blot of triplet sCRFR2α staining
and Ponceau red loading control. D Left panel: Representative
images from rat hypothalamic mixed primary cultures stained for
DAPI (blue), sCRFR2α (green), and GFAP (magenta) reveal cyto-
plasmic distribution of sCRFR2a in neuronal cells (GFAP negative)
and astrocytes (GFAP positive). Right panel: Accumulation of
sCRFR2α in end-boutons of astrocytic processes (white arrows)
might indicate releasable pools.
Chronic oxytocin-driven alternative splicing of Crfr2α induces anxiety
assessed whether the diminished availability of sCRFR2α
affects anxiety-related behavior. The GapmeRs were
designed to bind the Exon 5–7 boundary, which is exclu-
sively found in the mRNA of the soluble form of CRFR2α,
so that specific knockdown of sCRFR2α was achieved
(Fig. 5B). Fluorescent labeling of the infused GapmeRs
revealed predominantly intra-PVN staining, with some
diffuse signal scattered in the adjacent, mostly dorsal
hypothalamus, potentially representing cellular projections
originating from the PVN (Supplementary Fig. S5A).
Infusion of GapmeRs into the PVN caused a significant
reduction of sCRFR2α in the CSF after 7 days (Fig. 5C),
which was accompanied by a reduction in anxiety-like
behavior in the LDB reflected by an increased time spent in
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the light box and increased exploration of the center area of
the light box (Fig. 5D–F). In a complementary approach, we
upregulated sCRFR2α levels by TSBs, to promote alter-
native splicing of the Crfr2α mRNA to its shorter sCrfr2α
form. This was achieved by targeting TSBs to the endo-
genous splice sites up- and downstream of Exon 6, thus
enforcing the exclusion of Exon 6 from the pre-mRNA and
inducing a frame shift to form a premature termination
codon within Exon 7 (Fig. 5B). This process results in
predominant sCrfr2α mRNA levels, at the expense of
reduced mCrfr2α levels. TSB infusion bilaterally into the
PVN resulted in increased anxiety-related behavior of male
rats in the LDB (Fig. 5G, H).
Taken together, these results indicate that a low
mCRFR2α/high sCRFR2α ratio in the PVN is associated
with an anxiogenic phenotype. This was further sub-
stantiated by our observation of anxiolytic properties of
mCRFR2α, as activation of mCRFR2α by the agonist
(SCP), and blocking mCRFR2α with the antagonist (ASV)
produced anxiolytic and anxiogenic effects, respectively
(Supplementary Fig. S5B). Of note, the consequences of
altered mCRFR2α/sCRFR2α ratio appear to be specific for
anxiety, as social preference behavior, known to be
promoted by OXT [9, 54], was not affected by GapmeRs or
TSBs (Supplementary Fig. S5C). In summary, the identified
OXTR-ERK1/2-MEF2A-sCRFR2α intraneuronal pathway
may underlie the anxiogenic effect of chronic OXT treat-
ment in male rats.
Discussion
The brain OXT system has repeatedly been suggested as
target for the treatment of psychopathologies associated
with symptoms of anxiety [29, 40, 64]. Given that synthetic
OXT therapy would most likely involve chronic or repeated
application, detailed knowledge of the behavioral and
molecular processes downstream of the OXTR after chronic
OXT is indispensable.
In this study, we revealed that chronic icv OXT for 14 days
increases anxiety-like behavior in male and virgin female rats
in a sex- and dose-dependent manner. This central effect seems
to be of transient nature, as it disappeared after a 5-day
washout period. This together with the lack of an acute icv
OXT effect on anxiety-like behavior indicates a reversible
molecular mechanism within the brain that underlies the
anxiogenic effect of chronic OXT. We showed that the
anxiogenic effect in males is accompanied by the activation of
a novel intracellular signaling pathway involving increased
transcriptional activity of MEF2A, and subsequent alternative
splicing of Crfr2α into its soluble, anxiogenic, form. The
distinct role of sCRFR2α in anxiety regulation was confirmed
by targeted manipulations of Crfr2α splicing. While knock-
down of sCRFR2α within the PVN using GapmeRs reduced
anxiety, local upregulation of alternative splicing of Crfr2α
using TSBs increased anxiety, thus recapitulating the effect of
chronic OXT. We further showed by CRISPR-Cas9-guided
insertion of a HiBiT-tag into Exon 6 of the Crfr2α gene that
chronic OXT reduced membrane expression of mCRFR2α and
induced the release of sCRFR2α in vitro. In vivo, sCRFR2α
levels could be detected and quantified in the CSF, and were
found to positively correlate with anxiety-like behavior.
Although our results challenge the utility of chronic or repe-
titive OXT application as treatment option for anxiety-related
disorders, we could identify sCRFR2α as a novel target for
diagnosis and pharmacological intervention of these disorders.
The CRFR2α is predominantly expressed in the brain,
with a few exceptions in peripheral organs [65, 66]. One
characteristic of the shorter and soluble splice variant,
sCRFR2α, is its inability to incorporate into the cellular
membrane due to the lack of the transmembrane domain
and, therefore, high abundance in the cytosol from where it
can be released into the extracellular space [57, 67]. Pre-
vious publications have suggested that the process of
alternative splicing serves as a mechanism to control full-
length GPCR mRNA availability, which is in line with our
Fig. 5 Increased sCRFR2α release underlies the anxiogenic effect
of chronic OXT in combination with mild stress. A Representative
picture of Dot Blot analysis (for detailed methodology see Supple-
mentary Methods) of CSF (VEH and GapmeR) and control tissue
protein lysates (cerebellum=CB as negative control, PVN as positive
control, H2O). For detection, the sCRFR2α-specific antibody (pro-
vided by Joan Vaughan [57]) was used at a dilution of 1:20.000 in 5%
BSA. B Schematic representation of the rat Crfr2α gene, the trans-
membrane domain is indicated by a blue bar, including Exon 4 to
Exon 11. Target site blocker (TSB) binding sites are indicated by green
bars. Multiple MEF2 binding sites are indicated as red arrows. Exon 5/
7 boundary GapmeR binding site in the sCrfr2α mRNA is indicated in
yellow. C Infusion of GapmeRs targeting sCrfr2α bilaterally into the
PVN of male rats reduced sCRFR2α expression by ~50% as assessed
by Dot Blot in CSF samples. Data are shown as fold change in protein
expression ±SEM. One-tailed Student’s t test, t= 1.828, df= 12, *p=
0.046; n(scr)= 8, n(GapmeR)= 6. D Individual CSF sCRFR2α signal
intensity and % time spent in LB correlate negatively (R=−0.54,
ANOVA F(1;13)= 4.946, p= 0.046), suggesting that sCRFR2α is
anxiogenic. E GapmeR-induced reduction in sCRFR2α increased the
time spent in LB and inner zone of the OF, indicating anxiolysis.
Anxiety-like behavior was determined 7 (LDB) or 8 days (OF) after
GapmeR infusion. Data are represented as mean percentage of time
spent in the LB ± SEM (one-tailed t-test *p= 0.0486), and the mean
percentage of time in the inner zone of the OF (Mann–Whitney Rank
Sum Test U= 16.000, *p= 0.037) ±SEM; n(scr)= 10, n(GapmeR)=
8. F Representative heat maps showing the distribution of rat presence
in the light and dark compartment of the LDB or inner and outer zone
in the OF test. G Infusion of TSBs bilaterally into the PVN of male
rats and local induction of alternative splicing of Crfr2α enhanced
anxiety-like behavior of male rats in the LDB 7 days after infusion,
demonstrating an anxiogenic effect of sCRFR2α. Data are represented
as mean percentage of time spent in the LB ± SEM. t= 1.843; one-
tailed t-test *p= 0.0409; n(scr)= 10, n(TSB)= 10. H Representative
heat map of the distribution of rat presence in the LDB after VEH or
TSB treatment.
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data revealing the shifted ratio between sCRFR2α/
mCRFR2α after chronic OXT treatment [67, 68].
We found that OXT-induced changes in MEF2A activity
are involved in alternative splicing of Crfr2α, in line with
recent findings that MEF2A is part of a large complex of
transcription and splicing-regulating factors, such as Brg1/
Brm, BAF47, BAF170, BAF155, or MyoD. These factors
contribute to the correct transcription and immediate pro-
cessing of the transcript [69, 70]. Thus, our results support
the hypothesis that transcription and alternative splicing are
linked and co-dependent processes. Our data further suggest
that activation of MEF2A via dephosphorylation at Ser408
is crucial to drive alternative splicing of Crfr2α, as this
occurred only in the male 10 ng/h group and parallel to the
increase in anxiety. Interestingly, chronic OXT did not
activate MEF2A in female rats, although females appeared
to be more sensitive to the anxiogenic effects of chronic
OXT treatment than males. As a result, the mCRFR2α/
sCRFR2α ratio remained unaltered in females after chronic
OXT. Sexual dimorphism in OXT-induced anxiety has been
described before and appears to be rooted in differential
CRF signaling from OXTR-expressing interneurons in the
prefrontal cortex [59]. In more detail, OXT-induced
recruitment of CRF binding protein in the prefrontal cor-
tex acts anxiolytic in a sex-specific manner, as CRF binding
protein attenuates potentiation of postsynaptic layer 2/3
pyramidal cell activity only in male mice and, thereby,
brings about anxiolysis [59]. Although shorter in length,
sCRFR2α maintains its ability to bind the mCRFR2α and
CRFR1 ligands CRF, urocortin I and urocortin II with
nanomolar affinity [57], and thus could prevent them from
binding to mCRFR2α [24]. Consequently, scavenging
mCRFR2α ligands by sCRFR2α could weaken or prevent
the anxiolytic signal conveyed by mCRFR2α, and promote
anxiety-like behavior in males. However, in females,
chronic OXT-induced anxiety appears to be mediated
independent of MEF2A activation and sCRFR2α
production.
Importantly, we have detected sCRFR2α in rat brain CSF
and cell culture medium, proving that the release of
sCRFR2α into the extracellular space can be induced by
OXT. The observed correlation between CSF sCRFR2α
levels and anxiety-like behavior further supports our
hypothesis that the balance between soluble and membrane-
bound CRFR2α in the PVN in favor of the anxiogenic
soluble splice variant is instrumental in promoting anxiety
in male rats. Interestingly, we observed that brief exposure
to a mild stressor, i.e., the elevated platform 24 h prior to
testing, is required to induce anxiogenesis after chronic
OXT treatment. As mild stress promotes the incorporation
of anxiolytic mCRFR2α into the membrane [71–73],
chronic OXT might interfere with this process by shifting
the mCRFR2α/sCRFR2α ratio.
In conclusion, our study shows that chronic OXT dose-
dependently enhances anxiety-like behavior in males and
females, which involves the activation of the transcription
factor MEF2A and subsequent alternative splicing of
Crfr2α mRNA into the anxiogenic soluble form in male
rats. Consequently, these findings together with previous
data on adverse effects of chronic or repetitive OXT treat-
ment in rodents and humans [33–37, 51] need to be care-
fully considered, before using chronic or repetitive
administration of OXT for the treatment of psychopathol-
ogies. Our findings suggest that targeting sCRFR2α synth-
esis and release may open a more promising avenue for
future treatment options, particularly in men.
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